New developments in the diagnosis and treatment of Hymenoptera venom allergy

International Archives of Allergy and Immunology

Volumn 124, Issue 4, 2001, Pages 447-453

  Müller, Ulrich R ^a  

^a Spital Netz Bern   (Switzerland)

Author keywords

Antihistamines; Honeybee; Hymenoptera venom allergy; Mastocytosis; Recombinant venom allergens; Venom immunotherapy; Vespula

Indexed keywords

ACID PHOSPHATASE; ALLERGEN; ANTIHISTAMINIC AGENT; HYALURONIDASE; HYMENOPTERA VENOM; IMMUNOGLOBULIN E ANTIBODY; PHOSPHOLIPASE A1; PHOSPHOLIPASE A2; RECOMBINANT ALLERGEN; TERFENADINE; TRYPTASE; UNCLASSIFIED DRUG;

ALLERGIC REACTION; CLINICAL TRIAL; DIAGNOSTIC TEST; HONEYBEE; HUMAN; IMMUNITY; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; MAST CELL; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SKIN TEST; SYSTEMIC MASTOCYTOSIS;

ALLERGENS; ANIMALS; ARTHROPOD VENOMS; BEE VENOMS; DESENSITIZATION, IMMUNOLOGIC; HISTAMINE H1 ANTAGONISTS; HUMANS; HYMENOPTERA; HYPERSENSITIVITY, IMMEDIATE; MASTOCYTOSIS; RECOMBINANT PROTEINS; WASP VENOMS;

EID: 17744383998     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053779     Document Type: Review

References (51)

1. Mueller UR: Epidemiology of insect sting allergy; in Burr ML (ed): Epidemiology of Clinical Allergy. Monogr Allergy. Basel, Karger, 1993, vol 31, pp 131-146.
2. Charpin D, Birnbaum J, Vervloet D: Epidemiology of Hymenoptera allergy. Clin Exp Allergy 1994;24:1010-1015.
3. Sasvary T, Mueller U: Todesfälle an Insektenstichen in der Schweiz 1978 his 1987. Schweiz Med Wochenschr 1994;124:1887-1894.
4. Reisman RE, Wypych J, Arbesman CE: Stinging insect allergy: Detection and clinical significance of venom IgE antibodies. J Allergy Clin Immunol 1975;56:443-449.
5. Hunt KJ, Valentine MD, Sobotka AK, Bernton AW, Amodio FJ, Lichtenstein LM: A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-161.
6. Müller U, Thurnheer U, Patrizzi R, Spiess J, Hoigné R: Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979;34:369-378.
7. Ruëff F, Przybilla B, Mueller U, Mosbech H: The sting challenge test in Hymenoptera venom allergy. Allergy 1996;51:216-225.
8. Müller U, Helbling A, Berchtold E: Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-535.
9. Fang KSY, Vitale M, Fehlner P, King TP: cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc Natl Acad Sci USA 1988;85:895-899.
10. 1 with mammalian lipases. FEBS Lett 1993;320:145-149.
11. King TP, Lu G, Gonzalez M, Qian N, Soldatova L: Yellow jacket venom allergens, hyaluronidase and phospholipase: Sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy. J Allergy Clin Immunol 1996;98:588-600.
12. Monsalve RI, Lu G, King TP: Expressions of recombinant venom allergen, antigen 5 of yellowjacket (Vespula vulgaris) and paper wasp (Polistes annularis) in bacteria or yeast. Protein Expr Purif 1999;16:410-416.
13. Suck R, Weber B, Kahlert H, Hagen S, Cromwell O, Fiebig H: Purification and immunobiochemical characterization of folding variants of the recombinant major wasp allergen ves v5 (antigen 5). Int Arch Allergy Immunol 2000; 121:284-291.
14. 2 from honeybee venom glands. The deduced amino acid sequence reveals homology to the corresponding vertebrate enzymes. Eur J Biochem 1989;184:249-254.
15. 2. Biochim Biophys Acta 1992;1165:201-210.
16. Gmachl M, Kreil G: Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm. Proc Natl Acad Sci USA 1993; 90:3569-3573.
17. Soldatova LN, Crameri R, Gmachl M, Kemeny DM, Schmidt M, Weber M, et al: Superior biologic activity of the recombinant bee venom allergen hyaluronidase expressed in baculovirus-infected insect cells as compared with Escherichia coli. J Allergy Clin Immunol 1998; 101:691-698.
18. Soldatova LN, Bakst JB, Hoffman DR, Slater JE: Molecular cloning of a new honeybee venom allergen, acid phosphatase. J Allergy Clin Immunol 2000;105:S378.
19. 2 from honeybee venom is similar. J Allergy Clin Immunol 1995;96:395-402.
20. 2. Clin Exp Allergy 1997; 27:915-920.
21. 2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy. J Allergy Clin Immunol 1995;95:1229-1235.
22. Mueller UR, Soldatova L, Weber M: Bee venom allergy: Comparison of IgE-binding capacity of purified natural and recombinant-synthetic venom allergens. J Allergy Clin Immunol 1998;101:33.
23. Müller UR, Horat W, Wüthrich B, Conroy M, Reisman RE: Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol 1983;72:685-689.
24. Fricker M, Helbling A, Schwartz L, Mueller U: Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol 1997;100:11-15.
25. Oude Elberink JNG, de Monchy JGR, Kors JW, van Doormaal JJ, Dubois AEJ: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Imnumol 1997;99: 153-154.
26. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B: Basale Mastzell-Tryptase im Serum und Risiko der Insektengift-Allergic. Allergologie 1999;22:53-54.
27. Haeberli G, Weber M, Salvisberg B, Müller U: Tryptase serum levels in hymenoptera venom allergy - SGAI Kongress 2000. Allergologie 2000;23:147.
28. Jarisch R, Götz M, Sidl R, Stabel A, Zaje J, Wechsler-Fördös A: Reduction of side effects of specific immunotherapy; in Pichler WJ, Stadler BM, Dahinden C, Péoud AR, Frei PC, Schneider C, et al (eds): Progress in Allergy and Clinical Immunology. Proc 13th Int Congr Allergol Clin Immunol. Toronto/Bern, Hogrefe & Huber, 1989, pp 387-390.
29. Berchtold E, Maibach R, Mueller U: Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy 1992;22:59-65.
30. Herman D, Melac M: Effect of pretreatment with cetirizine on side effects from rush-immunotherapy with honey bee venom. Allergy 1996;51(suppl 31):68.
31. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J: Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997;100:458-463.
32. Reimers A, Hari Y, Müller U: Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: A double-blind, placebo-controlled trial. Allergy 2000;55:484-488.
33. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Mueller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
34. 2 in bee venom and peptide immunotherapy recovery by IL-2 and IL-5 in vitro. Allergy 1997;52(suppl 37):87.
35. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL: Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980;302:1213-1219.
36. Müller U, Hari Y, Berchtold E: Premedication with antihistamines may enhance efficacy of specific allergen immunotherapy. J Allergy Clin Immunol, in press.
37. Mueller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A: A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results. J Allergy Clin Immunol 1987;80: 252-261.
38. Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D: Recombinant allergens. Allergy 1998; 53:552-561.
39. 2: The major bee-venom allergen. J Allergy Clin Immunol 1992;90:42-51.
40. 2. Immunol 1993;150:3582-3591.
41. 2 epitopes using short or long overlapping synthetic peptides: Interest for specific immunotherapy. Clin Exp Allergy 1997;27:1016-1026.
42. 2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754.
43. Urbanek R, Forster J, Kuhn W, Ziupa J: Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatr 1985;107: 367-371.
44. Golden DBK, Addison BI, Gadde J, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989;84:162-167.
45. Haugaard L, Nörregaard OFH, Dahl R: In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991;87:699-702.
46. Mueller U, Berchtold E, Helbling A: Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991;87:702-709.
47. Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW: Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991;88:339-348.
48. van Halteren HK, van der Linden PWG, Burgers JA, Bartelink AKM: Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997;100: 767-770.
49. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Discontinuing venom immunotherapy: Outcome after five years. J Allergy Clin Immunol 1996;97: 579-587.
50. Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM: Discontinuing venom immunotherapy: Extended observations. J Allergy Clin Immunol 1998;101:298-305.
51. Lerch E, Mueller UR: Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-612.